The price of Citius Pharmaceuticals Inc. (NASDAQ:CTXR) shares last traded on Wall Street rose 2.07% to $0.93.
Based on available information, 3 analysts follow Citius Pharmaceuticals Inc. (NASDAQ:CTXR). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $4.00, we find $4.00. Given the previous closing price of $0.91, this indicates a potential upside of 339.56 percent. CTXR stock price is now -13.07% away from the 50-day moving average and -20.25% away from the 200-day moving average. The market capitalization of the company currently stands at $144.92M.
Among analysts, 0 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $5.33 as their price target over the next twelve months.
With the price target of $4, Maxim Group recently initiated with Buy rating for Citius Pharmaceuticals Inc. (NASDAQ: CTXR).
A total of 8.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CTXR stock. A new stake in Citius Pharmaceuticals Inc. shares was purchased by NUVEEN ASSET MANAGEMENT, LLC during the first quarter worth $451,000. GOLDMAN SACHS GROUP INC invested $226,000 in shares of CTXR during the first quarter. In the first quarter, RHUMBLINE ADVISERS acquired a new stake in Citius Pharmaceuticals Inc. valued at approximately $134,000. VERITION FUND MANAGEMENT LLC acquired a new stake in CTXR for approximately $78,000. CHELSEA COUNSEL CO purchased a new stake in CTXR valued at around $76,000 in the second quarter. In total, there are 73 active investors with 11.10% ownership of the company’s stock.
A candlestick chart of Citius Pharmaceuticals Inc. (NASDAQ: CTXR) showed a price of $0.9000 on Friday morning. During the past 12 months, Citius Pharmaceuticals Inc. has had a low of $0.77 and a high of $1.71. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.10, and a quick ratio of 7.10. The fifty day moving average price for CTXR is $1.0637 and a two-hundred day moving average price translates $1.1665 for the stock.
The latest earnings results from Citius Pharmaceuticals Inc. (NASDAQ: CTXR) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.06, missing analysts’ expectations of -$0.05 by -0.01. This compares to -$0.06 EPS in the same period last year. The company reported revenue of $8.67 million for the quarter, compared to $8.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.75 percent.
